Overview

Safety, Efficacy and Pharmacokinetics of ALD403

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

Alder Biopharmaceuticals, Inc.